Jefferies Raises Price Target for Alto Neuroscience to $25
Jefferies boosts Alto Neuroscience price target to $25, citing upcoming Phase II data and investor interest in its precision psychiatry treatments.
/ 913 items
#Healthcare↓
Truist Says Alkermes’ Alixorexton Data Lacks Detail Despite Phase 2 Success
Truist comments on Alkermes’ Phase 2 Vibrance-2 trial of alixorexton in narcolepsy type 2, noting "limited" details but strong patient engagement and maintaining a Buy rating with a $50 target.
Citi Boosts Eli Lilly Price Target to $1,500 on Strong Weight Loss Outlook
Citi raises Eli Lilly’s price target to $1,500, citing growing dominance in the weight loss market after a Medicare and Medicaid access deal and over $40B in potential peak sales.
Guggenheim Upgrades Grail to Buy with $100 Target on Galleri’s Market Leadership
Guggenheim upgrades Grail to Buy with a $100 price target, citing Galleri’s strong market position in multi-cancer early detection (MCED) despite ongoing regulatory and reimbursement challenges.
enGene Upgraded to Strong Buy on Promising Bladder Cancer Data
Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.
Neuphoria Explores Sale Options After Drug Trial Failure
Neuphoria Therapeutics initiates strategic review following failed clinical trial. Lynx1 Fund offers $5.20/share buyout as biotech company explores merger and partnership options.